Published: Jul 07, 2021 By Alex Keown
Collaborations are part of the life’s blood of clinical development as biopharma and life sciences companies partner and pool resources to develop novel therapies and treatments for a myriad of diseases.
This morning, multiple companies announced clinical and strategic collaborations.
PureTech Health to Harness BeiGene’s Checkpoint Inhibitor
Boston-based PureTech Health plc and
forged an alliance to assess the combination of BeiGene’s experimental checkpoint inhibitor tislelizumab with
PureTech s LYT-200, an experimental monoclonal antibody targeting galectin-9, as a potential treatment for difficult-to-treat solid tumor indications that are associated with poor survival rates. Galectin-9 is a widely expressed immune modulator in multiple tumor types that are difficult-to-treat tumor types.
SOPHiA GENETICS Advances Blood Cancer Genomic Testing With New Myeloid Solutions
Targets DNA variants and RNA fusion genes for blood cancers, including challenging variants CALR, CEBPA, ASXL1, FLT3
News provided by
Share this article
BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/
SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDM™ for Blood Cancers, novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics. The solutions target the most relevant DNA variants and RNA fusion genes for blood cancers, and come with SOPHiA DDM™ platform analysis, easing the identification of major biomarkers with secondary and tertiary analyses.
Vivan Therapeutics Announces the Appointment of Lilly Wollman to Its Board of Directors prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Vivan Therapeutics Announces the Appointment of Lilly Wollman to Its Board of Directors
My Personal Therapeutics Ltd. (trading as
Vivan Therapeutics), a global leader in personalised cancer therapeutics and in-vivo high throughput drug screening, is pleased to announce the addition of
Lilly Wollman to its distinguished board of directors.
Lilly Wollman is a seasoned team-builder and entrepreneurial leader with a 20-year track record in finance and investing. Currently, she is pursuing an MPhil in Computational Biology from the University of Cambridge and is dedicated to a second career solving complex problems in human health through the application of data science and machine intelligence. She is currently a research intern in the CRUK Early Detection Programme, and at the Milner Therapeutics Institute.